You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

December 8, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

WHO expands naloxone access to help manage opioid overdoses

In new guidelines, the World Health Organization (WHO) is recommending that countries significantly expand access to naloxone to help manage opioid overdoses. » Guideline details

NIH reports first experimental Ebola vaccine produces immune response

The first experimental Ebola vaccine has been shown to be safe and prompt an immune response in results from a National Institutes of Health (NIH) phase 1 clinical trial. The vaccine produced immune system responses and was well tolerated in the whole study cohort of 20 healthy adults. » Study results

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Drugs in Perspective: Myalept (metreleptin)

Myalept (metreleptin) is a leptin analogue with the same physiologic effects as leptin. Metreleptin was granted a priority review and was FDA approved on February 25, 2014, as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired
lipodystrophy. » Read about Myalept's place in therapy

 

RELATED ARTICLES

Opioid deaths dip while heroin deaths increase

Ebola clinical activity heats up with vaccine candidates in the works

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group